share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K：重大事件
美股SEC公告 ·  12/18 02:35

Moomoo AI 已提取核心訊息

CVS Health announced the early results of its $1.77 billion maximum tender offer for multiple series of senior notes. As of December 13, 2024, significant portions of the notes have been tendered, with acceptance rates ranging from 14.56% to 70.61% across different series.The company has elected to accept for purchase and make payment for validly tendered notes on December 18, 2024, subject to acceptance priority levels. Due to reaching the maximum tender offer amount, no additional notes are expected to be purchased after the early settlement date.The total consideration for each $1,000 principal amount will be calculated to yield a sum equal to the applicable U.S. Treasury reference security yield plus a fixed spread. Holders of accepted notes will receive the total consideration, including a $30 per $1,000 early tender payment, plus accrued interest.
CVS Health announced the early results of its $1.77 billion maximum tender offer for multiple series of senior notes. As of December 13, 2024, significant portions of the notes have been tendered, with acceptance rates ranging from 14.56% to 70.61% across different series.The company has elected to accept for purchase and make payment for validly tendered notes on December 18, 2024, subject to acceptance priority levels. Due to reaching the maximum tender offer amount, no additional notes are expected to be purchased after the early settlement date.The total consideration for each $1,000 principal amount will be calculated to yield a sum equal to the applicable U.S. Treasury reference security yield plus a fixed spread. Holders of accepted notes will receive the total consideration, including a $30 per $1,000 early tender payment, plus accrued interest.
西維斯健康宣佈其17.7億美元的多系列高級票據的提前認購結果。截至2024年12月13日，已提交了大量票據，各系列的接受率在14.56%到70.61%之間。公司已決定於2024年12月18日接受有效提交的票據進行購買並付款，具體以接受優先級爲準。由於達到最高認購金額，預計在提前結算日期之後將不再購買額外的票據。每1,000美元本金的總對價將計算出一個總和，該總和等於適用的美國財政參考證券收益率加上固定差額。接受的票據持有人將收到總對價，包括每1,000美元提前認購支付的30美元，以及應計利息。
西維斯健康宣佈其17.7億美元的多系列高級票據的提前認購結果。截至2024年12月13日，已提交了大量票據，各系列的接受率在14.56%到70.61%之間。公司已決定於2024年12月18日接受有效提交的票據進行購買並付款，具體以接受優先級爲準。由於達到最高認購金額，預計在提前結算日期之後將不再購買額外的票據。每1,000美元本金的總對價將計算出一個總和，該總和等於適用的美國財政參考證券收益率加上固定差額。接受的票據持有人將收到總對價，包括每1,000美元提前認購支付的30美元，以及應計利息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Oscar Health
    OSCR
    -- 14.190
    Clover Health
    CLOV
    -- 3.310
    西維斯健康
    CVS
    -- 44.920
    Alignment Healthcare
    ALHC
    -- 10.840
    聯合健康
    UNH
    -- 511.150

    解鎖榜首股票